DEFINITY RT (perflutren) by Lantheus Medical Imaging is ultrasound contrast activity [moa]. First approved in 2001.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
DEFINITY RT (perflutren) is an intravenous ultrasound contrast agent that enhances visualization of cardiac chambers and left ventricular opacification during echocardiography. It works by producing microbubbles that reflect ultrasound waves, improving image quality for diagnostic evaluation. The product is indicated for patients undergoing echocardiographic procedures who require enhanced contrast for cardiac assessment.
Product is in peak commercial lifecycle stage with established market position; team size likely stable with mature sales infrastructure.
Ultrasound Contrast Activity
Contrast Agent for Ultrasound Imaging
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
DEFINITY RT offers stable career opportunities in a mature, peak-stage diagnostic product with established market infrastructure and physician relationships. Roles emphasize market maintenance, physician engagement, and reimbursement optimization rather than launch or growth dynamics.
Worked on DEFINITY RT at Lantheus Medical Imaging? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo